| 生物活性 | β-catenin-IN-3 (Compound C2) is a selective β-catenin inhibitor that binds to a novel allosteric site on the surface of β-catenin with a KD value of 54.96 nM, selectively inhibits β-catenin and reduces its cellular burden by targeting this cryptic allosteric regulatory site, and significantly decreases the viability of β-catenin-driven cancer cells while triggering its degradation through the proteasome system in β-catenin-overexpressing cancer cells. | ||||||||||||||||||||||||
| IC50 & Target |
|
||||||||||||||||||||||||
| 体外研究 (In Vitro) |
β-catenin-IN-3 (24 h)以剂量依赖性方式降低 DLD1,SW480,HCT116,SW48,MCF10A 和 H460 细胞的活力,IC50s为 0.85 μM、1.35 μM、5.35 μM、3.45 μM 和 20 μM 以上。。 Cell Viability Assay
Western Blot Analysis
Immunofluorescence
|
||||||||||||||||||||||||
| 体内研究 (In Vivo) |
β-catenin-IN-3 (25 mg/kg, i.p., 35 天) 显著降低 DLD1 异种移植模型中β-catenin 依赖性肿瘤生长。 MCE has not independently confirmed the accuracy of these methods. They are for reference only. Animal Model: 6-week-old female NSG (NOD-SCID) mice were injected with 3 *106 DLD1 cells. Dosage: 25 mg/kg Administration: i.p., 35 days Result: Mice Did not display any signs of acute toxicity and body weight loss. Inhibition of tumor growth by β-catenin-IN-3 was noted after 20 days of treatment, after which the tumor volume of β-catenin-IN-3 treated mice did not increase exponentially. At day 35, the calculated tumor growth inhibition by β-catenin-IN-3 was 50% as compared to the vehicle. |
||||||||||||||||||||||||
| 性状 | 固体 | ||||||||||||||||||||||||
| 颜色 | White to off-white |
| 分子量 | 484.25 |
| 分子式 | C19H20Br2N2Os |
| CAS No. | 1005288-15-2 |
| 储存方式 | -20°C, protect from light, stored under nitrogen *In solvent: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen) |
|||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
| 运输条件 | Room temperature in continental US; may vary elsewhere. | |||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
溶液配制表
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
|
DMSO 中的溶解度 : 100 mg/mL (206.50 mM; 超声助溶; 吸湿的 DMSO 对产品的溶解度有显著影响,请使用新开封的 DMSO)
* 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
该溶液配制表仅适用于固体产品。对于液体产品,请根据标明的浓度或密度计算稀释方案。
|
||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
请在以下方框中输入您的动物实验信息后点击计算,可以得到母液配置方法和体内配方的制备方法:
比如您的给药剂量是10 mg/kg,每只动物体重20 g,给药体积100 μL, 一共给药动物10只,您使用的配方为 10% DMSO + 40% PEG300 + 5% Tween 80 + 45% Saline / PBS / ddH2O, 那么您的工作液浓度为2 mg/mL。
母液配置方法:2 mg 药物溶于 100 μL DMSO ( 母液浓度为 20 mg/mL ), 如您需要配置的浓度超过该产品的溶解度,请先与我们联系。
体内配方的制备方法: 取 100 μL DMSO 母液, 添加 400 μL PEG300 混匀澄清, 再加 50 μL Tween 80, 混匀澄清, 再加 450 μL Saline / PBS / ddH2O 混匀澄清
以上为“体内实验配液计算器”的使用方法举例,并不是具体某个化合物的推荐配制方式,请根据您的实验动物和给药方式选择适当的溶解方案。
方案所需的各类助溶剂如: DMSO, PEG300, PEG400, Tween 80, SBE-β-CD, 玉米油等, 均可在MolStrong网站点击购买。
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL Saline/PBS/ddH2O,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。